Melanoma Marker Antibody (NKI/beteb): sc-52704
- Melanoma Marker Antibody (NKI/beteb) is a mouse monoclonal IgG2b κ, cited in 6 publications, provided at 200 µg/ml
- recommended for detection of Melanoma of human origin by IF and IHC(P)
- See Melanoma Marker (HMB45): sc-59305 for Melanoma Marker antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP, m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Melanoma Marker Antibody (NKI/beteb) for IHC(P) applications. These reagents are now offered in bundles with Melanoma Marker Antibody (NKI/beteb) (see ordering information below).
QUICK LINKS
SEE ALSO...
Melanoma Marker Antibody (NKI/beteb) is a mouse monoclonal IgG2b antibody that detects Melanoma Marker in human samples through immunofluorescence (IF) and immunohistochemistry with paraffin-embedded sections (IHCP). Melanoma Marker is crucial for identifying malignant melanoma, a serious form of skin cancer that arises from melanocytes, the pigment-producing cells responsible for melanin synthesis. Understanding Melanoma Marker′s structure is vital, as Melanoma Marker plays a significant role in regulating cell proliferation and apoptosis, processes often dysregulated in cancer. Melanoma Marker′s structure includes specific domains that facilitate interaction with other cellular components, influencing signaling pathways that can lead to tumorigenesis. Anti-Melanoma Marker antibody (NKI/beteb) enables researchers to gain insights into melanoma development and progression, ultimately contributing to the advancement of targeted therapies and improved diagnostic strategies for this aggressive cancer type.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Melanoma Marker Antibody (NKI/beteb) References:
- Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens. | Perez, RP., et al. 2000. Hum Pathol. 31: 1381-8. PMID: 11112213
- Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. | Guerquin-Kern, JL., et al. 2004. Biomed Eng Online. 3: 10. PMID: 15068483
- Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies. | Tímár, J., et al. 2006. Cell Immunol. 244: 154-7. PMID: 17433276
- The new face of nucleolin in human melanoma. | Hoja-Łukowicz, D., et al. 2009. Cancer Immunol Immunother. 58: 1471-80. PMID: 19363676
- Identification of melanoma antigens using a Serological Proteome Approach (SERPA). | Suzuki, A., et al. 2010. Cancer Genomics Proteomics. 7: 17-23. PMID: 20181627
- Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay. | Blokzijl, A., et al. 2016. PLoS One. 11: e0154214. PMID: 27110718
- Generation of metastatic melanoma specific antibodies by affinity purification. | Schütz, B., et al. 2016. Sci Rep. 6: 37253. PMID: 27853253
- Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis. | Steppert, C., et al. 2020. Pathol Oncol Res. 26: 1777-1779. PMID: 31654227
- Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. | Audrey-Bayan, C., et al. 2020. Melanoma Res. 30: 410-415. PMID: 32379409
- Esophageal carcinoma with SMARCA4 mutation: a narrative review for this rare entity. | Xu, J. and Chi, Z. 2024. Transl Gastroenterol Hepatol. 9: 24. PMID: 38716209
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melanoma Marker Antibody (NKI/beteb) | sc-52704 | 200 µg/ml | $322.00 | |||
Melanoma Marker Antibody (NKI/beteb): m-IgG Fc BP-HRP Bundle | sc-536862 | 200 µg Ab; 10 µg BP | $361.00 | |||
Melanoma Marker Antibody (NKI/beteb): m-IgGκ BP-HRP Bundle | sc-534029 | 200 µg Ab; 40 µg BP | $361.00 | |||
Melanoma Marker Antibody (NKI/beteb): m-IgG2b BP-HRP Bundle | sc-549838 | 200 µg Ab; 10 µg BP | $361.00 |